Burning Rock Biotech Ltd (BNR)

Key Insights

• Yusheng Han, the director of Burning Rock Biotech, has acquired 314,870 ordinary shares (represented by American depositary shares) at a weighted average price of $17.36 on March 31, 2026, indicating his confidence in the company's prospects.
• The insider purchase represents a significant addition to Han's existing stake of 17,672,676 shares, suggesting he believes the stock is undervalued and has room for further appreciation.
• The transaction is notable as it represents a direct, open-market purchase by a director, which can be a positive signal for investors about the company's fundamentals and management's alignment with shareholder interests.